Collaboration and license agreements - (Additional Information) (Details) - USD ($) $ in Thousands |
1 Months Ended | 12 Months Ended | |
|---|---|---|---|
Nov. 30, 2023 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Collaboration revenue | $ 123,672 | $ 75,622 | |
| Research and Development Target Months | The Company expects that the remaining deferred revenue for the initial targets will be recognized within 21 months. The Company expects that deferred revenue related to replacement targets will be recognized within 33 months. Due to the uncertain nature of the research and development being performed by the Company, it may take longer than anticipated to recognize revenue related to the performance obligations for the initial and replacement targets. Any amounts remaining in deferred revenue will be recognized at the conclusion of the Roche Agreement in October 2028.As of December 31, 2025, potential research, development and regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price as they were fully constrained by uncertain events. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company will adjust its estimate of the transaction price. Any additions to the transaction price would be reflected in the period as a cumulative revenue catch-up based on the ratio of costs incurred to the total estimated costs expected applied to the revised transaction price. Sales-based royalties and milestone payments, which predominantly relate to the license, will be recognized if and when the related sales occur. | ||
| Milestone Payments | $ 60,000 | ||
| Deferred Revenue | 111,332 | 16,147 | |
| Liabilities Current | 64,212 | 156,946 | |
| Collaboration and License Agreement [Member] | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Non Refundable Upfront Payment | $ 50,000 | ||
| One Time Upfront Payment | 22,700 | ||
| Collaboration revenue | 46,300 | ||
| Liabilities Current | 10,600 | ||
| Liabilities Noncurrent | 12,100 | ||
| Collaboration and License Agreement [Member] | Collaboration Revenue [Member] | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Pre-Clinical Milestones | 3,000 | ||
| Collaboration and License Agreement [Member] | Research and Development Expense [Member] | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Non Refundable Upfront Payment Received | 9,000 | ||
| Pre-Clinical Milestones | 7,000 | ||
| Novartis License Agreement [Member] | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Collaboration revenue | 180,000 | ||
| Total transaction amount | 180,000 | ||
| Roche Agreement [Member] | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Deferred Revenue | 22,657 | 25,017 | |
| 2024 Novartis License Agreement [Member] | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Non Refundable Upfront Payment | 150,000 | ||
| Maximum Amount To Be Received In Total | $ 2,100,000 | ||
| Collaboration revenue | 150,000 | ||
| Profits And Losses Percentage | 30.00% | ||
| Total transaction upfront payment | $ 150,000 | ||
| Incremental cost reimbursements recognized as collaboration revenue | 1,200 | ||
| 2025 Novartis License Agreement [Member] | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Non Refundable Upfront Payment | 120,000 | ||
| One Time Upfront Payment | 120,000 | ||
| Collaboration revenue | $ 1,800 | ||
| Research and Development Target Months | The Company expects that that the remaining deferred revenue for the license and research services for a named immunology target and research services for two additional immunology targets to be recognized within 57 months. The deferred revenue related to material right license options will be recognized when Novartis exercises such options rights or at the expiration of the option rights. Due to the uncertain nature of the research and development being performed by the Company, it may take longer than anticipated to recognize revenue related to the performance obligations related to research services. | ||
| Collaboration funds receivable | $ 60,000 | ||
| Program and option exercise payments | 180,000 | ||
| Potential pre-clinical, clinical, commercial and sales milestones | 5,400,000 | ||
| Milestone Payments | 2,200,000 | ||
| Potential sales milestones payment | 3,200,000 | ||
| Deferred Revenue | 118,200 | ||
| Liabilities Current | 19,000 | ||
| Liabilities Noncurrent | 99,200 | ||
| 2025 Novartis License Agreement [Member] | Maintenance [Member] | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| One Time Upfront Payment | $ 60,000 | ||
| Minimum [Member] | Collaboration and License Agreement [Member] | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Potential clinical, commercial and sales milestones | 2,000,000 | ||
| Pre-clinical milestones | $ 172,000 | ||
| Minimum [Member] | 2024 Novartis License Agreement [Member] | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Potential clinical, commercial and sales milestones | $ 1,500,000 | ||